Skip to content
Screener

Emergent Biosolutions EBS Commercial Products — Total revenues

Other segment segments

MCM Products
$168M+188%

Similar metrics at other companies

Quanterix Corporation logo
QTRXProduct revenue — Total revenues
$23.48M+39.5%
Cactus logo
WHDProduct revenue — Total revenues
$297.24M+42.2%
Kinetik Holdings logo
KNTKProduct revenue — Total revenues
$312.23M-0.1%
Artivion logo
AORTProducts — Total revenues
$99.91M+14.3%
Flotek Industries logo
FTKProducts — Total revenues
$84.2M+57.7%
TGE
TGENProducts — Total revenues
$1.18M-53.6%

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$248.16M-47.4%
Enterprise value$695.46M-19.5%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenues reportable segments:
Commercial Products$52.4$67.5$95.3$112.8
MCM Products168.058.4269.8215.0
Reconciliation of revenue:220.4125.9365.1327.8
All other revenues (1)13.915.025.335.3
Total revenues$234.3$140.9$390.4$363.1
Cost of sales reportable segments:
Commercial Products (2)$36.2$36.2$63.0$60.7

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's commercial products — total revenues?
Emergent Biosolutions (EBS) reported commercial products — total revenues of $52.4M in Q2 2026.
How has Emergent Biosolutions's commercial products — total revenues changed year-over-year?
Emergent Biosolutions's commercial products — total revenues decreased by 22.4% year-over-year, from $67.5M to $52.4M.
What is the long-term trend for Emergent Biosolutions's commercial products — total revenues?
Over 4 years (2021 to 2025), Emergent Biosolutions's commercial products — total revenues has grown at a -15.2% compound annual growth rate (CAGR), from $438M to $226.1M.
What does commercial products — total revenues mean?
Represents the total gross income generated from the sale of goods within the commercial products business segment. This metric reflects the market demand and pricing power for the company's non-government healthcare and public health offerings.

Ask your AI about Emergent Biosolutions's commercial products — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude